Stock events for Sonoma Pharmaceuticals, Inc. (SNOA)
Over the past six months, Sonoma Pharmaceuticals' stock price has decreased by 42.22%, with a 52-week trading range between $1.75 and $6.92. In February 2026, Sonoma Pharmaceuticals reported its Third Fiscal Quarter 2026 Financial Results. In January 2026, the company welcomed a new member to its Board of Directors and a new Senior Vice President. In November 2025, Reliefacyn Advanced received the National Rosacea Society Seal of Acceptance. In November 2025, the company exhibited at MEDICA 2025 in Düsseldorf, Germany. In November 2025, Sonoma Pharmaceuticals reported its Second Fiscal Quarter 2026 Financial Results, noting the highest quarterly revenues in the company's history at $5.6 million. In October 2025, Sonoma Pharmaceuticals registered its manufacturing facility and listed a Microcyn-based facial spray under MoCRA. In October 2025, the company launched a new HOCl wound cleanser manufactured for Medline Industries, LP.
Demand Seasonality affecting Sonoma Pharmaceuticals, Inc.’s stock price
Information regarding specific demand seasonality for Sonoma Pharmaceuticals, Inc. products and services is not explicitly available.
Overview of Sonoma Pharmaceuticals, Inc.’s business
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products, leveraging its patented Microcyn® technology. These products are classified as medical devices and are available as prescription, over-the-counter (OTC), and office dispense products. The company's diverse product portfolio addresses a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, and animal health care, as well as non-toxic disinfectants. Major products include dermatology products like Epicyn Facial Cleanser and Levicyn Dermal Spray, wound and skin care products like Microcyn, eye care products like Acuiycn Eyelid and Eyelash Hygiene, animal health care products like MicrocynAH, disinfectants like Nanocyn, and oral care products like Endocyn.
SNOA’s Geographic footprint
Sonoma Pharmaceuticals is headquartered in Boulder, Colorado, United States, with manufacturing operations in Jalisco, Mexico, and European marketing and sales headquartered in Roermond, Netherlands. The company sells its products directly or through partners in 53 countries worldwide, with revenue contributions from the United States, Europe, Latin America, Asia, and other regions. The company has expanded its presence in the U.S. through over-the-counter channels with large retailers like Walmart and Amazon, and in Europe under updated medical device regulations.
SNOA Corporate Image Assessment
In the past year, Sonoma Pharmaceuticals has experienced positive developments impacting its brand reputation. Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel received the National Rosacea Society Seal of Acceptance in November 2025. The FDA cosmetic product facility registration and the listing of a Microcyn-based facial spray under MoCRA in October 2025 enhance the company's credibility. Sonoma Pharmaceuticals' products are reported to have improved outcomes for over ten million patients globally, contributing to a positive reputation.
Ownership
As of early March 2026, the ownership structure of Sonoma Pharmaceuticals (SNOA) includes institutional investors holding approximately 1.95% to 7.13% of the company's stock, insiders owning between 24.59% and 29.35% of the stock, and the general public and individual investors holding a significant portion, ranging from 63.52% to 92.5%. Major institutional owners include DRW Securities, LLC, Vanguard Group Inc, Geode Capital Management, Llc, McKinley Carter Wealth Services, Inc., and BlackRock, Inc. Among individual investors, Bruce Thornton is noted as owning the most shares.
